BOUNDLESS BIO, INC. Capital Expenditures Incurred but Not yet Paid
BOUNDLESS BIO, INC. (BOLD) reported Capital Expenditures Incurred but Not yet Paid of $22.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-09.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-03-09
- BOUNDLESS BIO, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $22.00K, a 8.33% decline year-over-year.
- BOUNDLESS BIO, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-12-31 was $294.00K.
- BOUNDLESS BIO, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-09-30 was -$1.00K.
- BOUNDLESS BIO, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-06-30 was $83.00K, a 12.16% increase year-over-year.
- BOUNDLESS BIO, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $400.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2025-03-31 | $22.00K 10-Q · filed 2025-05-09 | $316.00K derived: sum of 2 quarters · filed 2026-03-09 | $315.00K derived: sum of 3 quarters · filed 2026-03-09 | $398.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-12-31 | $294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $293.00K derived: sum of 2 quarters · filed 2026-03-09 | $376.00K derived: sum of 3 quarters · filed 2026-03-09 | $400.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $82.00K derived: sum of 2 quarters · filed 2025-11-05 | $106.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $107.00K 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $24.00K 10-Q · filed 2025-05-09 | |||
| 2023-09-30 | -$35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $39.00K derived: sum of 2 quarters · filed 2024-11-07 | $65.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $100.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $26.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |